Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Nov 2018
Randomized Controlled Trial Multicenter StudyMaintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
Psoriasis is a chronic disease that may require long-term treatment. Ixekizumab (IXE), which is a high-affinity monoclonal antibody that selectively targets interleukin 17A, is an approved therapy for patients with moderate-to-severe plaque psoriasis. ⋯ IXE sustained high responses with clearance of skin and nail lesions, with no new safety concerns through 3 years.